clinical 1,552 words KG: Als
Contents

Intravenous Immunoglobulin (IVIG) in ALS Trial

No AI portrait yet

Knowledge Graph

Agent Input

Related Hypotheses (130)

Lysosomal Membrane Repair Enhancement
Score: 0.54
Glymphatic System-Enhanced Antibody Clearance Reversal
Score: 0.54
Prohibitin-2 Mitochondrial Cross-Seeding Hub Disruption
Score: 0.47
SASP-Mediated Complement Cascade Amplification
Score: 0.98
Selective Acid Sphingomyelinase Modulation Therapy
Score: 0.98
Nutrient-Sensing Epigenetic Circuit Reactivation
Score: 0.97
AMPK hypersensitivity in astrocytes creates enhanced mitocho
Score: 0.82
Senescent Microglia Resolution via Maresins-Senolytics Combi
Score: 0.79
Selective HDAC3 Inhibition with Cognitive Enhancement
Score: 0.78
Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modu
Score: 0.77
SASP-Mediated Cholinergic Synapse Disruption
Score: 0.76
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.76
Near-infrared light therapy stimulates COX4-dependent mitoch
Score: 0.74
Epigenetic Memory Erasure via TET2 Activation
Score: 0.74
PARP1 Inhibition Therapy
Score: 0.74
SIRT3-Mediated Mitochondrial Deacetylation Failure with PINK
Score: 0.74
Senescence-Induced Lipid Peroxidation Spreading
Score: 0.73
TFAM overexpression creates mitochondrial donor-recipient gr
Score: 0.73
Sleep Spindle-Synaptic Plasticity Enhancement
Score: 0.72
Astroglial Gap Junction Coordination via Connexin-43 Phospho
Score: 0.72
← Prevpg 4/7Next →

Related Analyses (17)

TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
CRISPR-based therapeutic approaches for neurodegenerative di
neurodegeneration · archived
Microglial subtypes in neurodegeneration — friend vs foe
neuroscience · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · completed

Related Experiments (30)

Viral and Post-Infectious Mechanisms in ALS — Experiment Des
clinical · proposed · Score: 0.40
FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40
Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40

See Also (2)

A2M Gene
gene · KG edge: interacts_with
ABCA1 - ATP-Binding Cassette Transporter A1
gene · KG edge: activates

Knowledge Graph (12 edges)

CACNA1A associated_with Als
CHAT associated_with Als
MAP2 interacts_with Als
MAP1B interacts_with Als
MAP6 interacts_with Als
MAPT regulates Als
MAP6 associated_with Als
BACE1 therapeutic_target Als
DCX interacts_with Als
CDK5 activates Als

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

💬 Discussion (Talk page)

Loading comments...